- Trials with a EudraCT protocol (42)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
42 result(s) found for: Necrotizing Enterocolitis.
Displaying page 1 of 3.
EudraCT Number: 2019-002548-26 | Sponsor Protocol Number: 0139 | Start Date*: 2020-12-16 | ||||||||||||||||
Sponsor Name:Royal College of Surgeons in Irlenad | ||||||||||||||||||
Full Title: Can Pentoxifylline improve long-term outcomes in preterm infants with late-onset sepsis or necrotizing enterocolitis? A pragmatic, randomised, placebo controlled trial | ||||||||||||||||||
Medical condition: Late onset sepsis & necrotising enterocolitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: IE (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000754-22 | Sponsor Protocol Number: IBP-9414-020 | Start Date*: 2019-10-14 | |||||||||||
Sponsor Name:Infant Bacterial Therapeutics AB (IBT) | |||||||||||||
Full Title: A randomized, double blind, parallel-group, placebo controlled study to evaluate the efficacy and safety of IBP-9414 in premature infants 500-1500g birth weight in the prevention of necrotizing ent... | |||||||||||||
Medical condition: Necrotizing Enterocolitis (NEC) | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) HU (Completed) ES (Ongoing) BG (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000453-41 | Sponsor Protocol Number: BMBF-Fz01KG1602 | Start Date*: 2018-05-29 | |||||||||||||||||||||||||||||||
Sponsor Name:University Hospital Tuebingen | |||||||||||||||||||||||||||||||||
Full Title: Effects of closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C) on outcome of extremely preterm infants – a randomized controlled parallel group multicenter trial for safety... | |||||||||||||||||||||||||||||||||
Medical condition: Extremely low gestational age neonates (ELGANs), i.e. those who are born at <28 weeks gestation and who uniformly suffer from intermittent hypoxemic episodes. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003177-14 | Sponsor Protocol Number: IBUPAR-Trial | Start Date*: 2016-04-06 |
Sponsor Name: | ||
Full Title: Paracetamol versus ibuprofen in preterm infants with a hemodynamically significant patent ductus arteriosus: a randomized clinical trial. | ||
Medical condition: Persistent ductus arteriosus haemodynamically significant | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004228-70 | Sponsor Protocol Number: IBP-9414-010 | Start Date*: 2015-12-28 |
Sponsor Name:Infant Bacterial Therapeutics AB | ||
Full Title: A randomized, double blind, parallel-group, dose escalation placebo-controlled multicentre study to investigate the safety and tolerability of IBP-9414 administered in preterm infants | ||
Medical condition: Prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003202-77 | Sponsor Protocol Number: NEOKOFF22 | Start Date*: 2023-04-04 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name: | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: The effect of additional pre-extubational loading dose of caffeine-citrate | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Extubation failure and bronchopulmonary dysplasia | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: HU (Trial now transitioned) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002170-34 | Sponsor Protocol Number: 2004-002170-34 | Start Date*: 2006-03-29 |
Sponsor Name:Cambridge University Hospital (Addenbrookes Hospital) | ||
Full Title: "Ensayo clínico controlado randomizado sobre el tratamiento precoz con insulina en recién nacidos de muy bajo peso" | ||
Medical condition: Very low birth weight infants requiring intensive care have relative insulin deficiency often leading to hyperglycaemia during the first week of life. There is increasing evidence that the early po... | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-004890-29 | Sponsor Protocol Number: FIT-PIV | Start Date*: 2023-03-09 | |||||||||||
Sponsor Name:Elgan Pharma Ltd | |||||||||||||
Full Title: A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants | |||||||||||||
Medical condition: Gastro-intestinal malabsorption due to gastro-intestinal immaturity in preterm infants. | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005987-15 | Sponsor Protocol Number: The Triple P study | Start Date*: 2009-10-22 | |||||||||||
Sponsor Name:AMC Amsterdam | |||||||||||||
Full Title: Preventing preterm birth: Costs and effects of screening of healthy women with a singleton pregnancy for a short cervical length. | |||||||||||||
Medical condition: Preterm birth with healthy singleton pregnancies | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005717-36 | Sponsor Protocol Number: 1645-CI-057 | Start Date*: 2012-06-14 |
Sponsor Name:Instituto de Investigación Sanitaria La Fe | ||
Full Title: Extremely low gestational age neonates randomly an assigned to be blindly resuscitated with 21% vs. 60% oxygen: influence upon mortality and chronic conditions in the neonatal period. | ||
Medical condition: Preterm infants aged 30 weeks or less, who need resuscitation / stabilization maneuvers with positive pressure ventilation immediately after birth | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000735-80 | Sponsor Protocol Number: 2010-382 | Start Date*: 2011-05-16 |
Sponsor Name:Lene Drasbek Huusom | ||
Full Title: Administration of antenatal magnesium sulphate for prevention of cerebral palsy in preterm infants (MASP-STUDY) | ||
Medical condition: Moderate to severe cerebral palsy | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005791-35 | Sponsor Protocol Number: SHP633-302 | Start Date*: 2020-12-23 |
Sponsor Name:Shire | ||
Full Title: A 24-week Safety, Efficacy, Pharmacodynamic, and Pharmacokinetic Study of Teduglutide in Japanese Pediatric Subjects, Aged 4 Months Through 15 Years, With Short Bowel Syndrome Who Are Dependent on ... | ||
Medical condition: Treatment of short bowel syndrome dependent on parenteral support | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-003220-31 | Sponsor Protocol Number: 54463 | Start Date*: 2016-06-21 |
Sponsor Name:VU medical center, Amsterdam | ||
Full Title: Low dose aspirin in the Prevention of Recurrent Spontaneous Preterm Labour – the APRIL study | ||
Medical condition: Prevention of recurrent spontaneous preterm birth | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-007498-19 | Sponsor Protocol Number: COL-1620-302 | Start Date*: 2009-09-17 |
Sponsor Name:Columbia Laboratories, Inc | ||
Full Title: The Effect of Vaginal Progesterone Administration in the prevention of Preterm Birth in Women with Short Cervix, [also Known as: Vaginal progesterone bioadhesive gel (Prochieve)® Extending Gestatio... | ||
Medical condition: Preterm birth (less than or equal to 32 6/7 weeks gestation) | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-000896-30 | Sponsor Protocol Number: Uni-Koeln-439 | Start Date*: 2009-02-09 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: Surfactant application during spontaneous breathing with CPAP or during mechanical ventilation in the therapy of IRDS in premature infants <27 weeks | |||||||||||||
Medical condition: Idiopathic Respiratory Distress Syndrome (IRDS) in preterm infants | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004526-33 | Sponsor Protocol Number: PDARCT1 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Royal College of Surgeons in Ireland | |||||||||||||
Full Title: A Randomised Controlled Trial of Early Targeted Patent Ductus Arteriosus Treatment Using a Risk Based Severity Score | |||||||||||||
Medical condition: Patent Ductus Arteriosus | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001007-72 | Sponsor Protocol Number: 80-84800-98-41027 | Start Date*: 2017-07-06 |
Sponsor Name:Amsterdam UMC location AMC | ||
Full Title: Atosiban versus placebo in the treatment of late threatened preterm birth (APOSTEL VIII). | ||
Medical condition: Neonatal outcome in threatened preterm birth between 30 and 34 weeks of gestation. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004482-14 | Sponsor Protocol Number: P160917 | Start Date*: 2019-08-14 |
Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP) | ||
Full Title: Tocolysis in the management of preterm premature rupture of membranes before 34 weeks of gestation: a double-blinded randomized controlled trial | ||
Medical condition: Pregnant women with PPROM at 22 to 33 weeks gestation | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2010-020464-38 | Sponsor Protocol Number: PRENU | Start Date*: 2010-06-08 |
Sponsor Name:University of Oslo | ||
Full Title: Nutrition, growth and development among very preterm infants | ||
Medical condition: The main purpose of this study is to evaluate the effect of increased supply of energy, protein, vitamin A and the long chain polyunsaturated fatty acids DHA and AA to Very Low Birth Weight Infants... | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: NO (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004297-26 | Sponsor Protocol Number: C19-29 | Start Date*: 2020-04-17 |
Sponsor Name:Institut National de la Santé et de la Recherche Médicale (INSERM) | ||
Full Title: Prophylactic treatment of the ductus arteriosus in preterm infants by acetaminophen | ||
Medical condition: Patent ductus arteriosus | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Completed) EE (Completed) IE (Completed) FI (Completed) BE (Completed) PT (Completed) SE (Completed) HU (Completed) DK (Completed) GB (Not Authorised) NO (Completed) AT (Completed) GR (Completed) PL (Ongoing) IT (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
